A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed Greater Than or Equal to 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere-Based Chemotherapy.

Trial Profile

A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed Greater Than or Equal to 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere-Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Docetaxel; Doxorubicin; Epirubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2009 Planned end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top